skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

In addition to Sanofi, firms recalling OTC ranitidine products with documentation included in FDA's database updates through 9 January are Amneal Pharmaceuticals, Preferred Pharmaceuticals, which distributed products made by Amneal, and Granules India Ltd.

 

OTC_Zantac_And_Private_Label


Sanofi's recall of OTC Zantac due to contamination of the active ingredient ranitidine with a potential carcinogenic is so widespread the US Food and Drug Administration's documentation of the firm's actions doesn't identify quantities of containers or packages but refers only to "all lots" of the products.

Information on some other firms' recalls for private label and store brand copies of OTC Zantac in 75- and 150-mg ranitidine formulations added to the FDA's recalls database between mid-December and 8 January also doesn't include amounts, which the agency's typically does in its recall records. Rather than identify all lots as the products covered in the recalls, the firms' information includes lists of dozens of serial numbers and other identifying data.

In addition to Sanofi, firms recalling OTC ranitidine products with documentation included in the FDA's database updates for 11, 18 and 25 December and 2 and 8 January are Amneal Pharmaceuticals Inc, Preferred Pharmaceuticals Inc., which distributed products made by Amneal, and Granules India Ltd. (See table linked below.)

Ranitidine contamination and the FDA's response to the problem prompted Rep. Rosa DeLauro, D-CT, to ask that it keep the ingredient off the market and to re-introduced legislation proposing that the agency have mandatory recall authority for drugs.

Read also

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Start a free trial

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
General enquiry

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now